Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BESTOW kidney transplant tegoprubart versus tacrolimus study
2023-503336-41-00Phase 2Completed
- Sponsor
- Eledon Pharmaceuticals, Inc.
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of tegoprubart in kidney allograft rejection (2 arms), sponsored by Eledon Pharmaceuticals, Inc. Primary endpoint: Mean estimated glomerular filtration rate at 12 months. Started Oct 2023; status: completed.
02
Drugs
tegoprubart
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2023-503336-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503336-41-00.